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Recent studies (Shlush et al., 2014; Corces-Zimmerman et al., 2014) have demonstrated that leukemias
develop from hematopoietic stem cells that acquire preleukemic mutations, allowing clonal expansion and
subsequent acquisition of mutations leading to cancer. Preleukemic cells survive chemotherapy and serve
as reservoirs for disease, generating new clones and leading to relapse.Acute myeloid leukemia (AML) is a malig-
nancy in which hematopoietic stem and
progenitor cells (HSPCs) give rise to
clonal populations of primitive cancer
cells with impaired differentiation, known
as ‘‘blasts.’’ These clones vary in domi-
nance over time, some with distinct, and
others with overlapping, mutational pro-
files. The application of next-generation
sequencing to define the serial acquisition
of genetic mutations has allowed a pre-
liminary view of the evolution of primary
AML by The Cancer Genome Atlas
(TCGA) consortium (Cancer Genome
Atlas Research Network, 2013) and of
relapsed disease (Ding et al., 2012). Muta-
tional analysis of AML patient cohorts has
also begun to define the prognostic value
of these mutations (Patel et al., 2012).
However, an in-depth understanding of
the evolutionary origins of leukemic
clones is still lacking.
Two recent studies by the Dick (Shlush
et al., 2014) and Majeti (Corces-Zimmer-
man et al., 2014) groups nowdemonstrate
that HSPCs acquire preleukemic mu-
tations. These preleukemic stem cells
contribute to normal blood development,
harbor a selective growth advantage
compared to their nonmutated normal
stem/progenitor counterparts, and can
subsequently gain additional mutations
that confer full malignant potential
(Figure 1). The fundamental shift in
thinking provided by these collective
studies is the demonstration that nonma-
lignant precursors give rise to a collection
of preleukemic cells that persist after
treatment and generate multiple waves
of malignant clones over time. Some
of these new clones are related to the
original malignant clone, whereas others
resemble the preleukemic HSPCs but
contain a unique set of downstream
mutations and are independent from theoriginal dominant malignant clone. These
preleukemic HSPCs are classified as
nonmalignant based on their ability to
generate cells in nonmalignant lineages
(e.g., B and T cells).
Shlush et al. performed deep
sequencing on 103 candidate genes
frequently mutated in AMLs (Shlush
et al., 2014). They used normal T lympho-
cytes as a surrogate for the occurrence of
mutations in HSPCs and compared
mutational profiles to those obtained
from leukemic blasts in the same blood
sample. Using this methodology, they
demonstrated that somatic DNMT3A
mutations occur in an ancestral cell that
generates both T cells and the dominant
leukemic clone. DNMT3A mutations
were shown to occur in specific HSPC
populations including, but not limited to,
HSPCs from a relapsed patient, megakar-
yocyte-erythroid progenitors (MEPs) and
CD33+ myeloid cells from a patient in
remission, and MEPs from a patient at
diagnosis. Several patient blast samples
had mutations in NPM1 not found
in their normal T cells. Strikingly, NPM1
mutations were only observed with
DNMT3A mutations, further suggesting
that DNMT3A mutations are early events
in leukemogenesis.
The authors then demonstrated that
preleukemic HSPCs survive after chemo-
therapy. By comparing allelic fre-
quencies of DNMT3Amut at times of diag-
nosis, remission, and relapse, they found
increasedprevalence of themutated allele
at remission and relapse, suggesting that
these early, preleukemic cells harboring
DNMT3Amut could be a reservoir for
recurrent disease. Furthermore, using
xenograft repopulation assays, Shlush
et al. established that DNMT3Amut-
bearing HSPCs engraft and generate
long-term multilineage reconstitution,Cell Stem Ceand they demonstrated that these cells
possess a competitive repopulation
advantage over nonmutated HSPCs,
similar to previous observations showing
that murine Dnmt3a-deficient HSPCs
demonstrate a growth advantage over
wild-type cells (Challen et al., 2012).
Previous work from the Majeti group,
analyzing a small cohort of AML patients,
suggested that preleukemic mutations
are present in HSPCs (Jan et al., 2012).
Expanding on this earlier work, Corces-
Zimmerman et al. (2014) now identify
preleukemic mutations in FACS-purified
HSPCs from a larger cohort of patients
manifesting a broader spectrum of AML.
Similar to the Dick group, they found
that ‘‘preleukemic’’ HSPCs can generate
long-term myeloid and lymphoid engraft-
ment in mice. The authors define muta-
tions in IDH2, DNMT3A, ASXL1, and
IKZF1 in the HSPC population and in
leukemic cells, and in certain cases, in a
fraction of sorted B and T cells at diag-
nosis. This indicates a clear contribution
of the preleukemic HSPCs to overall he-
matopoiesis. The authors observe distinct
patterns of mutation acquisition, with
about half of the recurring mutations
being classified as early, mostly in genes
involved in DNA methylation, chromatin
modification, and chromatin topology,
and the other half of mutations classified
as late, mostly within genes encoding pro-
teins important in cell signaling and prolif-
eration. Similar to the findings of the Dick
group, the authors find that DNMT3A
mutations were present in preleukemic
HSPCs in 75% of patients, and addition-
ally, that 80% of patients also harbored
preleukemic IDH1/2 mutations. These
mutations are found in the heterozygous
state, implying that they can have domi-
nant effects over the normal allele (Kim
et al., 2013).ll 14, April 3, 2014 ª2014 Elsevier Inc. 421
Figure 1. On the Origin of Leukemic Species
A model for the clonal origin and evolution of AML emerges from the work by
Shlush et al. (2014) and Corces-Zimmerman et al. (2014), which describes
sequential rounds of clonal expansion from a preleukemic stem cell pool.
Hematopoietic stem cells (HSPCs; blue circles) gain mutations in epigenetic
modifiers (designated by ‘‘X’’) to become preleukemic HSPCs (darker blue
circles), which reside in a unique bone marrow niche (shown in yellow high-
lighting) and enjoy a growth advantage over normal HSPCs. Preleukemic
stem cells have the capacity to differentiate into multiple cell types, including
myeloid and lymphoid derivatives. Overt leukemia develops when preleuke-
mic HSPCs accumulate oncogenic mutations (designated ‘‘X+’’) over time.
Chemotherapy induces clinical remissions by killing the leukemia cells, but
the expanded pool of preleukemic HSPCs remains. With time, a new clonal
expansion may emerge, leading to clinical relapse. A major challenge for
modern approaches to achieving long-term remissions is the eradication of
the preleukemic stem cell pool.
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merman et al. found that
preleukemic HSPCs are not
eradicated by chemotherapy.
Using bone marrow samples
from patients in remission,
as well as from patients
with relapsed disease, the
authors find that preleuke-
mic HSPCs survive chemo-
therapy, persist during remis-
sion, and generate new
waves of clones leading to
relapse. They also found
new mutations acquired dur-
ing relapse that were not
present at diagnosis or dur-
ing remission, indicating that
in some cases, a different
HSPC clone may lead to the
origin of relapsed disease.
Majeti and colleagues make
the important point that
there are multiple pathways
to relapsed AML (Corces-
Zimmerman et al., 2014):
cells that are refractory to
initial therapy; clonal evolu-
tion from the original clone;
growth of new subclones pre-
sent at diagnosis; and new
clones arising from a preleu-
kemic HSPC.These studies raise additional ques-
tions.For instance,will similar evolutionary
patterns be identified for AMLs driven by
recurring translocations or mutations
other than DNMT3A or IDH2? What other
early mutations drive the development of
preleukemic HSPCs? Given that normal
HSPCs acquiremutationswith age (Welch
et al., 2012), howoften do thesemutations
generate HSPCs? TET2, another gene in
the epigenetic pathway, for example, can
be mutated in elderly individuals with
clonal hematopoiesis but without overt
malignancy (Busque et al., 2012). Do mu-422 Cell Stem Cell 14, April 3, 2014 ª2014 Eltations that generate a preleukemic
HSPC population always involve a gene
that encodes a chromatin-remodeling
protein?HowdoesAMLarise frompreleu-
kemic HSCs that show no genetic muta-
tions? What additional pathways lead to
disease relapse?
Reflecting on Darwin’s writing, ‘‘I have
called this principle, by which each slight
variation, if useful, is preserved, by the
term of Natural Selection...,’’ it is remark-
able to think that this statement is still
relevant to our work today, more than
150 years after Darwin’s words were pub-sevier Inc.lished in 1859. One can
almost imagine that Darwin
wrote in response to the find-
ings of these two outstanding
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